Catheter Precision Inc. reported total revenue of $226,000 for the third quarter of 2025, an increase of 135% compared to $96,000 in the same period of 2024. Revenue for the first nine months of 2025 was $581,000, up 114% from $271,000 in the first nine months of 2024. The GAAP net loss for the third quarter of 2025 was $2.3 million, a 45% reduction from $4.1 million in the third quarter of 2024. For the first nine months of 2025, the GAAP net loss was $11.4 million compared to $11.0 million for the same period in 2024. Business developments for the period included increased sales activities for the LockeT device outside the United States, following CE Mark approval, with new interest in several European countries and South Africa. Five accounts in South Africa placed reorders in October. Sales of the VIVO product line also expanded internationally, with the first purchase order from France in October. The company completed two VIVO clinical studies in 2025 and continued to prioritize clinical studies and publications.